Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Penicillamine

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44338   clinical trials with a EudraCT protocol, of which   7368   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    29 result(s) found for: Penicillamine. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2016-003876-29 Sponsor Protocol Number: GMPO-131-002 Start Date*: 2017-05-16
    Sponsor Name:Orphalan
    Full Title: CHELATE STUDY: Trientine tetrahydrochloride (TETA 4HCl) for the treatment of Wilson’s disease
    Medical condition: Wilson's disease (WD) is a life-threatening inborn error of copper metabolism leading to an excessive copper accumulation, mainly in the liver or brain, causing hepatic and neurologic severe symptoms.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10047988 Wilson's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) DE (Completed) GB (GB - no longer in EU/EEA) AT (Completed) IT (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2020-005832-31 Sponsor Protocol Number: ALXN1840-HV-Cu-Absorption Start Date*: 2021-04-13
    Sponsor Name:Alexion Pharmaceuticals Inc.
    Full Title: Efficacy of ALXN1840 on human hepatic copper uptake quantified with 64CuCl2 PET/CT-scan.
    Medical condition: Healthy Volunteers (Wilson's disease)
    Disease: Version SOC Term Classification Code Term Level
    22.0 10022891 - Investigations 10022891 Investigations SOC
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2013-003564-31 Sponsor Protocol Number: UNV-TRI-002 Start Date*: 2014-02-27
    Sponsor Name:Univar B.V.
    Full Title: Multicentre, Retrospective and Prospective Study to Assess Long Term Outcomes of Chelator-Based Treatment With Trientine in Wilson Disease Patients Withdrawn from Therapy With d-Penicillamine
    Medical condition: Wilson disease, also known as hepatolenticular degeneration, a rare automsomal, recessively inherited disorder which results in chronic copper intoxication.
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004850 10047988 Wilson's disease LLT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2007-001190-28 Sponsor Protocol Number: KCL (Rheum) TACIT Version 2.1 Start Date*: 2007-05-09
    Sponsor Name:King's College London
    Full Title: Randomised controlled trial of tumour-necrosis-factor inhibitors against combination intensive therapy with conventional disease modifying anti-rheumatic drugs in established rheumatoid arthritis
    Medical condition: Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10039073 Rheumatoid arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2017-004135-36 Sponsor Protocol Number: WTX101-301 Start Date*: 2018-03-23
    Sponsor Name:Wilson Therapeutics AB
    Full Title: A Phase 3, Randomised, Rater-Blinded, Multi-Centre Study to Evaluate the Efficacy and Safety of WTX101 Administered for 48 Weeks Versus Standard of Care in Wilson Disease Subjects Aged 18 and Older...
    Medical condition: Wilson Disease
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Prematurely Ended) CZ (Prematurely Ended) FR (Completed) AT (Prematurely Ended) ES (Prematurely Ended) HU (Prematurely Ended) PL (Prematurely Ended) PT (Completed) SE (Prematurely Ended) BE (Completed) DK (Prematurely Ended) NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2004-000482-35 Sponsor Protocol Number: ARA102198 Start Date*: 2004-10-11
    Sponsor Name:GlaxoSmithKline Research & Development Ltd.
    Full Title: A randomised, double-blind, placebo-controlled, parallel group study to investigate the anti-inflammatory and metabolic effects of rosiglitazone XR, 8mg once daily, in subjects with rheumatoid arth...
    Medical condition: Rheumatoid Arthritis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) LT (Completed)
    Trial results: View results
    EudraCT Number: 2005-000549-13 Sponsor Protocol Number: VX04-702-301 Start Date*: 2005-05-03
    Sponsor Name:Vertex Pharmaceuticals Incorporated
    Full Title: A 12-Week, Double-Blind, Randomized, Parallel Group, Placebo-Controlled Study of Two Doses of VX-702 in Subjects with Moderate to Severe Rheumatoid Arthritis
    Medical condition: rheumatoid arthritis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2020-004604-33 Sponsor Protocol Number: TR-004 Start Date*: 2021-02-23
    Sponsor Name:Univar Solutions, B.V.
    Full Title: Open label, Multicenter, Prospective Study to Characterize the Pharmacokinetics and Pharmacodynamics of Cufence (Trientine Dihydrochloride) and to Investigate the Efficacy and Safety in Wilson’s Di...
    Medical condition: Wilson Disease
    Disease: Version SOC Term Classification Code Term Level
    22.1 10010331 - Congenital, familial and genetic disorders 10019819 Hepato-lenticular degeneration PT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) DK (Trial now transitioned) FR (Trial now transitioned) PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-003711-60 Sponsor Protocol Number: ALXN1840-WD-205 Start Date*: 2021-01-15
    Sponsor Name:Alexion Pharmaceuticals, Inc
    Full Title: A Phase 2, single-arm, pathologist-blinded study using liver biopsy specimens to assess copper concentration and histopathologic changes in patients with Wilson disease who are treated with ALXN184...
    Medical condition: Wilson's Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10047988 Wilson's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) DK (Completed) GB (GB - no longer in EU/EEA) FR (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2004-003771-37 Sponsor Protocol Number: Hx-CD20-403 Start Date*: 2006-03-03
    Sponsor Name:Genmab A/S
    Full Title: A double-blind, randomized, placebo controlled, dose escalation, multi-center phase I/II trial of HuMax-CD20, a fully human monoclonal anti-CD20 antibody, in patients with active rheumatoid arthrit...
    Medical condition: Active Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    7.0 10039073 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: View results
    EudraCT Number: 2012-003439-41 Sponsor Protocol Number: VX12-509-103 Start Date*: 2013-04-11
    Sponsor Name:Vertex Pharmaceuticals Incorporated
    Full Title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of VX 509 using Magnetic Resonance Imaging and Arthroscopic Biopsi...
    Medical condition: Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    16.1 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: LT (Completed) EE (Completed) DK (Completed) NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-000102-25 Sponsor Protocol Number: ALXN1840-WD-Cu-Excretion Start Date*: 2021-04-09
    Sponsor Name:Aarhus University Hospital
    Full Title: Efficacy of ALXN1840 on human biliary copper excretion quantified with 64CuCl2 PET/MR-scan
    Medical condition: Wilson's Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10047988 Wilson's disease LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2010-019872-65 Sponsor Protocol Number: MK-0663-108 Start Date*: Information not available in EudraCT
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase III, Two-Part, Randomized, Double-Blind, Active Comparator-Controlled, Multicenter Clinical Trial to Study the Relative Efficacy and Tolerability of Two Doses of MK-0663/Etoricoxib in Patie...
    Medical condition: Ankylosing Spondylitis (AS)
    Disease: Version SOC Term Classification Code Term Level
    17.0 10028395 - Musculoskeletal and connective tissue disorders 10002556 Ankylosing spondylitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) FI (Completed) BE (Completed) AT (Completed) GB (Completed) EE (Completed) SK (Completed) CZ (Completed) LT (Completed)
    Trial results: View results
    EudraCT Number: 2013-003984-72 Sponsor Protocol Number: M13-537 Start Date*: 2014-05-30
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Investigate the Safety and Efficacy of ABT-494 with Background Methotrexate (MTX) in Subjects with Active Rheumatoid Arthritis (RA) ...
    Medical condition: Rheumatoid Arthritis (RA)
    Disease: Version SOC Term Classification Code Term Level
    17.1 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Completed) HU (Completed) CZ (Completed) SK (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2007-005434-37 Sponsor Protocol Number: IM101-174 Start Date*: 2008-07-24
    Sponsor Name:Bristol Myers Squibb International Corporation
    Full Title: A Phase IIIB Multicenter, Randomized, Double-Blind, Double-Dummy Study to Compare the Efficacy and Safety of Abatacept Administered Subcutaneously and Intravenously in Subjects with Rheumatoid Arth...
    Medical condition: RHEUMATOID ARTHRITIS, NOS
    Disease: Version SOC Term Classification Code Term Level
    9.1 10039073 Rheumatoid arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) IE (Completed) HU (Completed) GB (Completed) BE (Completed) DE (Completed) NL (Completed) IT (Completed) AT (Prematurely Ended) GR (Completed)
    Trial results: View results
    EudraCT Number: 2007-007859-14 Sponsor Protocol Number: ARRAY-162-201 Start Date*: 2008-05-22
    Sponsor Name:Array BioPharma Inc.
    Full Title: A 12-WEEK, PHASE 2, RANDOMIZED, DOUBLE-BLIND, MULTICENTER, PLACEBO CONTROLLED STUDY TO INVESTIGATE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF ARRY-438162, ADMINISTERED ORALLY DAILY IN PATIENTS WI...
    Medical condition: Active Rheumatoid Arthritis incompletely responsive to methotrexate
    Disease: Version SOC Term Classification Code Term Level
    9.1 10039073 Rheumatoid arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2010-019871-31 Sponsor Protocol Number: MK-0663-107 Start Date*: 2010-10-18
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase III, Two-Part, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Clinical Trial to Assess the Relative Efficacy and Tolerability of Two Doses of MK- 0663/Etoricoxib in Patients wit...
    Medical condition: Rheumatoid Arthritis (RA)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) BE (Completed) AT (Completed) LT (Completed) GB (Completed) DE (Completed) SK (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2020-005266-34 Sponsor Protocol Number: UX701-CL301 Start Date*: 2022-02-11
    Sponsor Name:Ultragenyx Pharmaceutical Inc.
    Full Title: A Randomized, Double-blind, Placebo-controlled, Multicenter, Seamless, Adaptive, Safety, Dose-finding, and Phase 3 Clinical Study of UX701 AAV-mediated Gene Transfer for the Treatment of Wilson Dis...
    Medical condition: Wilson disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10047988 Wilson's disease LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Trial now transitioned) PT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2009-011206-42 Sponsor Protocol Number: INCB 28050-201 Start Date*: 2009-08-18
    Sponsor Name:Incyte Corporation
    Full Title: A Randomized, Double Blind, Placebo Controlled, Dose Ranging, Parallel Group, Phase 2 Study of INCB028050 Compared to Background Therapy in Patients with Active Rheumatoid Arthritis with Inadequate...
    Medical condition: Active Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: View results
    EudraCT Number: 2004-002846-36 Sponsor Protocol Number: A3921019 Start Date*: 2005-06-14
    Sponsor Name:Pfizer Pharma GmbH
    Full Title: A PHASE 2A, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO COMPARE 3 DOSE LEVELS OF CP 690,550 VERSUS PLACEBO, ADMINISTERED ORALLY TWICE DAILY (BID) FOR 6 WEEKS, IN THE TREATME...
    Medical condition: Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    7.1 10039073 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed) SK (Completed) AT (Completed) ES (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 24 22:32:02 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA